US Stock MarketDetailed Quotes
ATXI Avenue Therapeutics
- 2.2900
- +0.0500+2.23%
Close Nov 7 16:00 ET
3.28MMarket Cap0.06P/E (TTM)
2.2900High2.1900Low8.58KVolume2.2600Open2.2400Pre Close19.12KTurnover0.67%Turnover RatioLossP/E (Static)1.43MShares26.467552wk High0.69P/B2.95MFloat Cap1.700052wk Low--Dividend TTM1.29MShs Float13882.2750Historical High--Div YieldTTM4.46%Amplitude1.7000Historical Low2.2280Avg Price1Lot Size
About Avenue Therapeutics Company
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Company Profile
SymbolATXI
Company NameAvenue Therapeutics
Listing DateJun 27, 2017
Issue Price6.00
Founded2015
CEODr. Alexandra MacLean, M.D.
MarketNASDAQ
Employees3
Fiscal Year Ends12-31
Address1111 Kane Concourse,Suite 301
CityBay Harbor Islands
ProvinceFlorida
CountryUnited States of America
Zip Code33154
Phone1-781-652-4500
Websitehttp://www.avenuetx.com
Company Executives
- Name
- Position
- Salary
- Dr. Alexandra MacLean, M.D.
- Director and Chief Executive Officer
- 1.21M
- David Jin
- Principal Accounting Officer, Interim Chief Financial Officer and Chief Operating Officer
- 260.00K
- Dr. Jay D. Kranzler, M.D.
- Chairman of the Board
- 212.19K
- Dr. Lindsay A. Rosenwald, M.D.
- Director
- 104.00K
- Neil Herskowitz
- Independent Director
- 164.00K
- Faith L. Charles
- Independent Director
- 154.00K
- Curtis G. Oltmans
- Independent Director
- 154.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data